Nicotinamide Mononucleotide (NMN) — Complete Research Guide
TL;DR
NMN is a precursor to NAD+, a molecule essential for cellular energy production that declines with age. Human trials consistently show it raises blood NAD+ levels and is generally well tolerated. The strongest outcome data include improved muscle insulin sensitivity in postmenopausal women with prediabetes, and supportive signals for walking speed and sleep quality in older adults. Evidence for broad athletic performance is limited. Evidence rating: ⭐⭐⭐⭐ Strong for NAD+ elevation; ⭐⭐⭐ Promising for selected metabolic and functional outcomes.
Evidence Rating: ⭐⭐⭐⭐ Strong for raising NAD+; ⭐⭐⭐ Promising for muscle insulin sensitivity (specific populations) and functional markers in older adults; ⭐⭐ Limited for general performance enhancement.
What NMN Is
Nicotinamide mononucleotide is a nucleotide derived from vitamin B3 (niacin). It sits directly upstream of NAD+ in the salvage pathway. Because NAD+ is required for mitochondrial ATP production, sirtuin activity and DNA repair, maintaining NAD+ levels is of interest for cellular energy and healthy ageing.
NMN for Healthy Ageing
NAD+ declines with chronological age. Trials in older adults show that 250 mg/day NMN raises blood NAD+, may help maintain walking speed, and can improve sleep quality scores. These functional markers are relevant to independence and quality of life with age. Large trials with multi-year healthspan or lifespan endpoints are still lacking.
→ Learn more in our full research summary: “NMN for Healthy Ageing”
NMN for Foundational Health
The most consistent human finding is reliable elevation of circulating NAD+ and related metabolites. This makes NMN a rational foundational support for cellular energy status, particularly as we age or experience metabolic stress.
→ Learn more in our full research summary: “NMN for Foundational Health”
NMN for Women’s Health
The highest-quality metabolic outcome trial to date (Yoshino et al., 2021, Science) was conducted in postmenopausal women with prediabetes. Ten weeks of 250 mg/day NMN significantly improved muscle insulin sensitivity and insulin signalling. This remains the clearest clinical signal for NMN in a specific demographic.
→ Learn more in our full research summary: “NMN for Women’s Health”
NMN for Performance & Energy
Some trials report improved walking distance at higher doses. However, systematic reviews have not found consistent benefits for muscle mass or strength. NMN should be viewed as cellular energy support rather than a classic performance enhancer. Claims in this area carry clear caveats.
→ Learn more in our full research summary: “NMN for Performance & Energy”
Expert Views
Dr. David Sinclair has been a leading researcher and advocate for NAD+ biology and precursors including NMN.
Dr. Peter Attia discusses NAD+ precursors with measured interest, emphasising mechanistic promise alongside the need for more robust long-term human data.
Dr. Rhonda Patrick has covered NAD+ metabolism in the context of cellular energy and ageing.
Practical Dosage
- Common effective range: 250–600 mg per day
- Higher doses (600–900 mg) used in some trials for functional outcomes
- Morning dosing is typical; consistency matters
- No loading phase required
Safety & Notes
NMN has demonstrated a good short-to-medium-term safety profile in human trials. Mild digestive symptoms are occasionally reported. Long-term data beyond several months remain limited. Consult your healthcare provider before use.
Key References
- Yoshino M. et al. (2021). Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women. Science, 372(6547), 1224–1229. DOI: 10.1126/science.abe9985
- Igarashi M. et al. (2022). Chronic nicotinamide mononucleotide supplementation elevates blood NAD+ and alters muscle function in healthy older men. npj Aging, 8, 5. DOI: 10.1038/s41514-022-00084-z
- Yi L. et al. (2023). The efficacy and safety of β-nicotinamide mononucleotide supplementation in healthy middle-aged adults. GeroScience, 45, 29–43. DOI: 10.1007/s11357-022-00705-1
- Pencina K.M. et al. (2023). Nicotinamide adenine dinucleotide augmentation in overweight or obese middle-aged and older adults. J Clin Endocrinol Metab, 108(8), 1968–1980. DOI: 10.1210/clinem/dgad027
- Morifuji M. et al. (2024). Ingestion of β-nicotinamide mononucleotide increased blood NAD levels, maintained walking speed, and improved sleep quality in older adults. GeroScience, 46(5), 4671–4688. DOI: 10.1007/s11357-024-01204-1
- Prokopidis K. et al. (2025). The effect of nicotinamide mononucleotide and riboside on skeletal muscle mass and function. J Cachexia Sarcopenia Muscle. DOI: 10.1002/jcsm.13799
This is not medical advice. BioHackNZ provides general information based on published research. NMN is a complementary supplement and is not intended to diagnose, treat, cure, or prevent any disease. Always consult your healthcare provider before starting any supplement regimen. Individual results vary.
Last updated: 22 August 2026 | BioHackNZ Research Team
Shop Nicotinamide Mononucleotide (NMN)
View Product →